Le Lézard
Classified in: Health
Subjects: CCA, ACC

Invitation - Presentation of Sobi's Q1 2020 Results


STOCKHOLM, April 22, 2020 /PRNewswire/ --  On 29 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobitm) will publish its report for the first quarter 2020. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CEST. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:
SE: +46-8-505-583-58
UK: +44-333-300-9272
US: +1-646-722-4904

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same URL.

About Sobitm

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact
Paula Treutiger
Head of Communication & Investor Relations
+46-733-666-599
[email protected]

Linda Holmström
Corporate Communication & Investor Relations
+46-708-734-095
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation---presentation-of-sobi-s-q1-2020-results,c3094418

The following files are available for download:

https://mb.cision.com/Main/14266/3094418/1233924.pdf

Invitation to presentation of Q1 2020 results

SOURCE Swedish Orphan Biovitrum AB


These press releases may also interest you

at 10:28
On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue...

at 10:28
In a groundbreaking leap forward in the realm of nutrition and fitness technology, Portions Master announces the launch of its revolutionary app, set to transform the way individuals approach portion control and nutritional tracking....

at 10:21
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative...

at 10:17
The life insurance comparison site QuickQuote.com recently published a guide to accidental death and dismemberment (AD&D) insurance. It revealed that some plans cost only $4 a month and provide $100,000 in coverage....

at 10:15
Options Medical Weight Losstm, the nation's premier medical weight loss clinic and provider of medical weight loss solutions, is proud to announce its second clinic in the Metro Atlanta area at 3651 Peachtree Parkway, Suite B. The clinic cordially...

at 10:15
The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global MRSA drugs market size reached US$ 3.8...



News published on and distributed by: